ASH 2021 | Axi-cel as second-line therapy for R/R large B-cell lymphoma
Jason Westin
• 12 Dec 2021
Axicabtagene ciloleucel (axi-cel), an autologous anti‑CD19 chimeric antigen receptor (CAR) T-cell therapy, is currently only approved for third-line therapy in large B-cell lymphoma (LBCL). Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, comments on data from the Phase III ZUMA-7 trial (NCT03391466) which assessed axi-cel in patients with relapsed/refractory (r/r) LBCL. The primary endpoint, event-free survival (EFS), was met after a 24 month follow-up, suggesting that axi-cel should be moved to second-line therapy as the standard of care. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
